Elmind Capital LP Acquires 120,000 Shares of Urogen Pharma $URGN

Elmind Capital LP lifted its holdings in shares of Urogen Pharma (NASDAQ:URGN) by 120.0% in the first quarter, HoldingsChannel.com reports. The fund owned 220,000 shares of the company’s stock after acquiring an additional 120,000 shares during the period. Urogen Pharma makes up 1.1% of Elmind Capital LP’s investment portfolio, making the stock its 23rd largest position. Elmind Capital LP’s holdings in Urogen Pharma were worth $3,956,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hennion & Walsh Asset Management Inc. grew its position in Urogen Pharma by 148.4% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 161,924 shares of the company’s stock valued at $3,792,000 after buying an additional 96,741 shares during the period. SG Americas Securities LLC raised its position in Urogen Pharma by 20.3% in the first quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock worth $29,808,000 after acquiring an additional 280,199 shares during the period. Rice Hall James & Associates LLC boosted its stake in Urogen Pharma by 8.8% in the fourth quarter. Rice Hall James & Associates LLC now owns 281,876 shares of the company’s stock valued at $6,602,000 after acquiring an additional 22,733 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Urogen Pharma in the fourth quarter valued at about $26,350,000. Finally, DNB Asset Management AS bought a new position in shares of Urogen Pharma during the 4th quarter valued at approximately $397,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the insider owned 119,763 shares in the company, valued at $4,790,520. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 25,222 shares of company stock worth $892,661. Insiders own 4.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on URGN shares. HC Wainwright restated a “buy” rating on shares of Urogen Pharma in a research note on Thursday, July 9th. UBS Group reissued a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Oppenheimer raised their target price on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. The Goldman Sachs Group restated a “neutral” rating and issued a $44.00 target price on shares of Urogen Pharma in a research note on Wednesday, July 15th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a research report on Tuesday, March 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $41.62.

Urogen Pharma Stock Up 1.2%

NASDAQ URGN opened at $41.46 on Tuesday. The company’s 50 day moving average is $34.11 and its 200-day moving average is $25.82. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $43.93. The firm has a market cap of $2.02 billion, a P/E ratio of -15.08 and a beta of 1.56.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $50.96 million for the quarter, compared to analysts’ expectations of $44.83 million. Equities analysts expect that Urogen Pharma will post -0.76 EPS for the current year.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.